GSK announces CHMP of EMA adopted positive opinion of Jemperli

GSK announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion recommending approval of Jemperli in combination with carboplatin-paclitaxel, for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high, MSI-H, primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “We are pleased with this positive CHMP opinion and the potential for dostarlimab with chemotherapy to treat patients with this very challenging form of endometrial cancer. If approved, dostarlimab plus chemotherapy will be the first new treatment option in decades for these patients in the European Union, offering long-awaited new hope for improved long-term outcomes. This opinion further reinforces our confidence in dostarlimab’s important role in the immuno-oncology treatment landscape.”